# Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients

> **NCT00038142** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 46 (actual)

## Conditions studied

- Ewing's Sarcoma

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Cyclophosphamide
- **DRUG:** Dexrazoxane
- **BIOLOGICAL:** ImmTher

## Key facts

- **NCT ID:** NCT00038142
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1997-11
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Low Accrual
- **Last updated:** 2020-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038142, "Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00038142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*